» Articles » PMID: 25295235

A Quantitative and Qualitative Evaluation of the British Columbia Take Home Naloxone Program

Overview
Journal CMAJ Open
Specialty General Medicine
Date 2014 Oct 9
PMID 25295235
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In August 2012, the British Columbia Take Home Naloxone (BCTHN) program was introduced to help to reduce opioid overdose and its consequences. This study evaluates the BCTHN program, identifying the successes and challenges of implementing a provincial program in Canada.

Methods: In this cross-sectional study, we reviewed the records of the BCTHN administrative program to report on program outcomes (participation and overdose reversals). Focus groups and individual interviews were conducted with 40 clients in Vancouver; 12 individual interviews were completed with service providers, police officers and parents of people who use opioids from both the Vancouver and Interior regions of British Columbia. Qualitative data were analyzed using content analysis and a qualitative descriptive approach.

Results: As of March 13, 2014, the BCTHN program had been implemented at 40 sites, trained 1318 participants in overdose prevention, recognition and response, distributed 836 kits to clients and received reports of 85 overdose reversals. Stakeholders were supportive of the program, and clients reported greater confidence in response to overdose. Service providers found the program training materials easy to use and that training increased client engagement. Some of the challenges included difficulty in identifying physician willing to prescribe, recruitment of some at-risk populations (e.g., long-term opioid users and patients with chronic pain), and clients' reluctance to call 911. We also found that the police had some misconceptions about BCTHN.

Interpretation: The BCTHN program was easy to implement, empowering for clients and was responsible for reversing 85 overdoses in its first 20 months. We suggest communities across Canada should consider implementing take-home naloxone programs and evaluate their findings.

Citing Articles

Increases in housing rules and surveillance during COVID-19: impacts on overdose and overdose response in a community-based cohort of sex workers who use drugs in Vancouver, BC.

McDermid J, Pearson J, Braschel M, Moreheart S, Marck R, Shannon K Harm Reduct J. 2024; 21(1):153.

PMID: 39175071 PMC: 11342539. DOI: 10.1186/s12954-024-01030-w.


Evaluation of a large-scale health department naloxone distribution program: Per capita naloxone distribution and overdose morality.

Freiermuth C, Ancona R, Brown J, Punches B, Ryan S, Ingram T PLoS One. 2023; 18(8):e0289959.

PMID: 37566565 PMC: 10420337. DOI: 10.1371/journal.pone.0289959.


Sweden's first Take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals.

Holmen E, Warnqvist A, Kaberg M Subst Abuse Treat Prev Policy. 2023; 18(1):24.

PMID: 37087485 PMC: 10121425. DOI: 10.1186/s13011-023-00533-2.


Expanding the accessibility of harm reduction services in the United States: Measuring the impact of an automated harm reduction dispensing machine.

Arendt D J Am Pharm Assoc (2003). 2022; 63(1):309-316.

PMID: 36549931 PMC: 9870941. DOI: 10.1016/j.japh.2022.10.027.


Characteristics of and Experience Among People Who Use Take-Home Naloxone in Skåne County, Sweden.

Troberg K, Isendahl P, Alanko Blome M, Dahlman D, Hakansson A Front Public Health. 2022; 10:811001.

PMID: 35359781 PMC: 8960176. DOI: 10.3389/fpubh.2022.811001.


References
1.
Caplehorn J, Dalton M, Haldar F, Petrenas A, Nisbet J . Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse. 1996; 31(2):177-96. DOI: 10.3109/10826089609045806. View

2.
Seal K, Downing M, Kral A, Singleton-Banks S, Hammond J, Lorvick J . Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health. 2003; 80(2):291-301. PMC: 3456285. DOI: 10.1093/jurban/jtg032. View

3.
Green T, Heimer R, Grau L . Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction. 2008; 103(6):979-89. PMC: 3163671. DOI: 10.1111/j.1360-0443.2008.02182.x. View

4.
Dunn K, Saunders K, Rutter C, Banta-Green C, Merrill J, Sullivan M . Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010; 152(2):85-92. PMC: 3000551. DOI: 10.7326/0003-4819-152-2-201001190-00006. View

5.
Coffin P, Sullivan S . Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities. J Med Econ. 2013; 16(8):1051-60. DOI: 10.3111/13696998.2013.811080. View